MEI Pharma Company Profile (NASDAQ:MSHL)

About MEI Pharma (NASDAQ:MSHL)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MSHL
  • CUSIP: N/A
  • Web:
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%
  • Net Margins: -967.26%
  • Return on Equity: -32.95%
  • Return on Assets: -30.14%

Frequently Asked Questions for MEI Pharma (NASDAQ:MSHL)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MSHL."

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:

  • Christine Anna White M.D., Independent Chairman of the Board
  • Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
  • Brian G. Drazba, Chief Financial Officer, Secretary
  • David M. Urso, Senior Vice President of Corporate Development, General Counsel
  • Robert D. Mass M.D., Chief Medical Officer
  • Charles V. Baltic III, Independent Director
  • Kevan E. Clemens Ph.D., Independent Director
  • Nicholas R. Glover Ph.D., Independent Director
  • Thomas C. Reynolds M.D. Ph.D., Independent Director
  • William Dodge Rueckert, Independent Director

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEI Pharma stock can currently be purchased for approximately $0.42.

MarketBeat Community Rating for MEI Pharma (NASDAQ MSHL)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MEI Pharma (NASDAQ:MSHL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for MEI Pharma (NASDAQ:MSHL)
Price Target History for MEI Pharma (NASDAQ:MSHL)
Analysts' Ratings History for MEI Pharma (NASDAQ:MSHL)
No equities research coverage for this company has been tracked by


Earnings History for MEI Pharma (NASDAQ:MSHL)
No earnings announcements for this company have been tracked by


Earnings Estimates for MEI Pharma (NASDAQ:MSHL)
Current Year EPS Consensus Estimate: $-0.2600 EPS


Dividend History for MEI Pharma (NASDAQ:MSHL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for MEI Pharma (NASDAQ:MSHL)
No insider trades for this company have been tracked by


Headline Trends for MEI Pharma (NASDAQ:MSHL)
Latest Headlines for MEI Pharma (NASDAQ:MSHL)
DateHeadline logoMEI Pharma (MSHL) vs. Dermira (DERM) Financial Comparison - September 19 at 10:28 PM logoValeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA - June 30 at 2:01 AM logoMEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma - May 31 at 7:00 PM logoMEI Pharma's blood cancer candidate ME-401 performs well in early-stage study; shares up 4% - May 31 at 7:00 PM logoMEI Pharma (MEIP) Says Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in CCL and Follicular Lymphoma - May 31 at 8:58 AM logoBRIEF-MEI Pharma Inc files for mixed shelf of up to $150 million - May 5 at 9:28 AM logoAcute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report 2017 - Growing Interest in the Genetics of AML - Research and Markets - April 26 at 6:37 PM logoGlobal Acute Myeloid Leukemia (AML) Therapeutics - Pharmaceuticals - April 26 at 6:37 PM logoMEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer - April 3 at 10:05 AM logoBRIEF-MEI Pharma posts Q2 earnings per share $0.32 - February 8 at 7:31 PM logoBRIEF-MEI pharma reports fiscal year 2016 results - September 6 at 10:58 AM logoMEI Pharma net loss improves in FY16 - September 6 at 10:58 AM logoCDC grants $2.4 mln to five U.S. jurisdictions to fight Zika - September 3 at 8:42 AM logoBRIEF-Helsinn Investment Fund reports 7.1 pct passive stake in MEI Pharma - SEC filing - August 23 at 10:41 AM logoBRIEF-Alphabet - Google CEO Sundar Pichai reports open market sale of Co's class A common stock and class C capital stock - August 22 at 6:16 PM logoMEI Pharma +48% on leukemia drug deal - August 9 at 9:29 AM logo15 Biggest Mid-Day Gainers For Monday - August 8 at 1:22 PM logo11 Stocks Moving In Monday's Pre-Market Session - August 8 at 8:49 AM logoMEI Pharma's Pracinostat Gets Breakthrough Therapy Status For Its Pracinostat In Combination With Azacitidine - August 1 at 10:56 AM logoMEI Pharma's (MEIP) Pracinostat Receives FDA Breakthrough Therapy Designation - August 1 at 10:56 AM logoBRIEF-MEI pharma's pracinostat receives FDA's breakthrough therapy designation - August 1 at 10:56 AM logoDon’t trade like I do’: Buy shares in Teck Resources instead - February 27 at 1:55 PM



MEI Pharma (MSHL) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.